A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors

Running, not enrolling · Phase 1

Conditions studied: Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck, Renal Cell Carcinoma

In brief

This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of AB248 as monotherapy OR in combination with pembrolizumab in adult participants with locally advanced or metastatic solid tumors. The study will consist of a dose escalation and a dose expansion stage.

Key facts

Study ID

NCT05653882

Run by

Asher Biotherapeutics, Inc.

People needed

552

Starts

2023-01-04

Expected to finish

2027-05-01

Last updated by the study team

2025-09-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years of age at the time consent is signed.
• Has adequate end organ function per laboratory testing.
• Pregnancy prevention requirements
• Has measurable disease per RECIST 1.1 as assessed by the local site Investigator/radiology.
• Has a performance status of 0 or 1 on Eastern Cooperative Oncology Group scale.
• Histologic documentation of incurable, locally advanced or metastatic tumor of the type being evaluated in individual cohorts

You may not qualify if…

• Has a diagnosis of immunodeficiency.
• Has a history of a previous, additional malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 5 years.
• Has known active CNS metastases and/or carcinomatous meningitis.
• Has an active autoimmune disease that has required systemic treatment in the past 2 years.
• Has an active infection requiring systemic therapy.
• Inability to comply with study and follow-up procedures.
• Has had a severe hypersensitivity reaction (Grade ≥3) to treatment with pembrolizumab, another monoclonal antibody, or has history of any hypersensitivity to any components of the study treatments or any of their excipients.
• Has received prior systemic anticancer therapy including investigational agents within 4 weeks (or, if shorter, within 5 half-lives for kinase inhibitors) prior to first dose of study treatment.
• Has received prior radiotherapy within 2 weeks of start of study treatment or has had a history of radiation pneumonitis.
• Receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment.
• Has received previous treatment with another agent targeting the IL-2, IL-7, or IL-15 receptors.
• Is expected to require any other form of antineoplastic therapy while on study

Where it is running

• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• City of Hope — Duarte, California, United States
• UCLA — Los Angeles, California, United States
• UCSD — San Diego, California, United States
• UCSF — San Francisco, California, United States
• Yale — New Haven, Connecticut, United States
• University of Miami — Miami, Florida, United States
• Ocala Oncology Center — Ocala, Florida, United States
• University of Chicago Medical Center — Chicago, Illinois, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Karmanos Cancer Institute — Detroit, Michigan, United States
• Washington University — St Louis, Missouri, United States
• Rutgers — New Brunswick, New Jersey, United States
• NYU — New York, New York, United States
• UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina, United States
• Providence Cancer Institute Franz Clinic — Portland, Oregon, United States
• Sarah Cannon Research Institute — Nashville, Tennessee, United States
• Intermountain Health — Murray, Utah, United States
• Virginia Commonwealth — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.